Artificial intelligence is accelerating drug development and lowering costs across the pharmaceutical industry, potentially boosting operating profits by more than 10%, according to Bernstein.

Swiss pharma Roche is staying in lockstep with Eli Lilly, expanding its AI offerings and Nvidia partnership shortly after the ...

Designing an efficient platform is crucial for any industrial process. This design process is known as process development, and it has become increasingly important in the pharmaceutical industry at ...

Roche's rollout of thousands of Nvidia chips is the latest example of a pharmaceutical giant trying to use AI to discover and manufacture new therapies faster.

SandboxAQ is a company that many pharma and biotech professionals will be keeping an extremely close eye on in the coming years. Having SandboxAQ emerged as an independent company following spin-off ...

Drug discovery has traditionally been a reductive process—narrowing down, filtering out, and optimizing within established constraints. Generative AI turns that on its head. It is an expansive force, ...

Forbes contributors publish independent expert analyses and insights. Gil Press writes about technology, entrepreneurs and innovation. Will AI transform the typical trials and tribulations of drug ...

Scientists at the University of Cambridge have developed a new way to alter complex drug molecules using light rather than ...

Over the next 5 years, Gland Pharma plans to invest approximately Rs 20 bn in capex, primarily towards BFS and ophthalmic ...

Cloudbreak Pharma, Inc. ( (HK:2592)) has shared an update. Cloudbreak Pharma Inc. announced that its subsidiary, ADS Therapeutics LLC, has submitted an investigational new drug application to the U.S.